

AD-A283 853



AD _____



CONTRACT NO: DAMD17-87-C-7146


TITLE: CHEMOTHERAPY AND DRUG TARGETING IN THE TREATMENT
OF LEISHMANIASIS

PRINCIPAL INVESTIGATOR: Linda L. Nolan

CONTRACTING ORGANIZATION: University of Massachusetts
Amherst, Massachusetts 01003

REPORT DATE: November 30, 1992

TYPE OF REPORT: Annual Report



PREPARED FOR: U.S. Army Medical Research, Development,
Acquisition and Logistics Command (Provisional),
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 5

94-26559



568

94 8 19 085

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE 30 November 1992	3. REPORT TYPE AND DATES COVERED Annual Report (5/15/91-10/30/92)		
4. TITLE AND SUBTITLE Chemotherapy and Drug Targeting in the Treatment of Leishmaniasis		5. FUNDING NUMBERS Contract No. DAMD17-87-C-7146		
6. AUTHOR(S) Linda L. Nolan				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Massachusetts Amherst, Massachusetts 01003		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional), Fort Detrick, Frederick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words) The objective of this research was to test promising compounds for antileishmanial activity and to test for potential host toxicity with use of human CEM T4 cells. Growth experiments and testing for inhibition of parasite unique enzyme systems were employed in this study.				
14. SUBJECT TERMS Leishmania, DNA Polymerase; Made of action of Purine Analog, Biotechnology, Infectious Diseases, Antiparasitic Drugs, Chemotherapy			15. NUMBER OF PAGES	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

TABLE OF CONTENTS

• Abstract	1
• Military Significance.....	2
• Introduction.....	3
• Compounds Tested Against <u>Leishmania Mexicana</u>	10
• Compounds Tested Against Human CEM T4 Cells (IC50 uM).....	13
• The Toxicity of 34 Adalogsto Human CD4 T-Lymphocytes as Measured in ug/ml.....	16
• Enzyme Studies on DNA Polymerases from L. mexicana 227.....	17
• Compounds Tested Against Human CEM T4 Cells (IC50 uM).....	19
• Compounds for L. Mexicana (IC50, uM).....	26
• WRAIR Compound BJ 23346 Against Leshmania mexicana DNA Polymerase A and Chinese Hamster Ovary DNA Polymerase.....	35
• Results and Discussion.....	42
• Reference.....	50
• Distribution List.....	53

Accession For	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

MILITARY SIGNIFICANCE

The need for leishmanicides cannot be overemphasized. At present chemotherapy is dependent on a relatively small number of synthetic drugs. Resistance has been reported to occur against all these drugs and development of resistance to one compound is often accompanied by cross-resistance to others. In the chemotherapy of visceral and cutaneous leishmaniasis, the choice of drugs is very limited and success of a particular drug appears to vary from locality to locality, presumably due to strain differences in Leishmania.

To date the logical design of antiparasitic drugs has proved largely unsuccessful with the exception of purine metabolism in protozoa. While mammalian cells are capable of de novo synthesis of purines, many parasites do not synthesize purines but use salvage pathways. Analogues inhibiting key enzymes in purine pathway should, therefore, provide novel therapeutic agents. Purines and pyrimidines serve not only as precursors of RNA and DNA, but also as stores of high energy phosphate, constituents of certain coenzymes, and modulators of various enzymatic reactions. In view of this vital role, intervention of their metabolism will have profound effects on the organism.

To date there is no safe, effective, and quality-controlled antiparasitic vaccines. Membrane antigens differ from one species to another and during the course of infection, making the production of a useful vaccine very difficult.

The elucidation of the biochemical mode of action of promising compounds and the identification of unique enzyme systems will permit the logical design of more effective derivatives and also will provide insight on the mechanism of drug resistance. This information may allow a therapy program to be developed which would decrease or eliminate the problem of drug resistance.

Targeting of already promising compounds may increase the efficacy of these compounds for the various disease states of leishmaniasis and be more cost effective than the development of more than one drug.

Targeting will also allow the reduction in toxicity of certain compounds, and also be more cost effective since less drug should be required.

INTRODUCTION

Leishmaniasis is caused by protozoan parasites of the Order Kinetoplastida: Family-Trypanosomatidae. The disease is estimated to affect 12 million people in Third World countries. *Leishmania* extracellular forms (promastigotes) are injected into human skin during bites by the sandfly vector. Promastigotes are phagocytized by reticuloendothelial cells, within which the parasites transform into intracellular amastigotes. Human disease results from multiplication of amastigotes within macrophages. Present therapy with pentavalent antimony is potentially toxic, and often ineffective. One rationale for searching for alternative treatment is to identify a unique enzyme system and to target this system for chemotherapeutic exploitation.

Many of the enzymes involved in the synthesis of nucleic acids of the parasitic protozoans have been found to be unique, and for this reason we have begun studies to compare the DNA synthetic enzymes of parasitic protozoa to the mammalian polymerases.

During this research year we tested a number of compounds for Walter Reed Institute of Research (WRAIR) for antileishmanial activity.

We have developed a human CEM T₄ in vitro assay to determine the toxicity of promising antileishmanial compounds for host cells. Because T₄ cells are extremely important in eliciting the immune response, it is of profound importance that these cells are not compromised during chemotherapy of a parasitic disease. Use of our assay system can save WRAIR expensive and time-consuming *in*

vivo animal testing and provide critical data on promising compounds.

We also continued our investigations of the DNA polymerases of the leishmanial parasite because (1) these enzymes are unique from host enzymes and (2) they are extremely important in parasite survival. Compounds which are shown to be inhibitory to leishmanial DNA polymerases and exhibit low toxicity in the CEM T₄ system are potential candidates as therapeutic agents.

METHODS

Cultures of parasitic protozoa. Promastigotes of *Leishmania mexicana* Walter Reed strain 227, were maintained in this laboratory in tissue culture flasks containing the defined medium of Steiger and Black (1) supplemented with 5% heat-inactivated fetal calf serum (Gibco Laboratories, Grand Island, New York) and 50 mg/L gentamycin. The cells were grown at 26°C and subcultured weekly.

Cultures of T₄ cells. Human lymphocyte CEM T₄ cells were obtained from the Department of Pharmacology at the University of Massachusetts Medical Center. They were cultured in tissue flasks containing RPMI 1640 medium (Sigma Chemical Co., St. Louis, Missouri) supplemented with 0.1% sodium Bicarbonate, 5% heat-inactivated fetal calf serum, and 50 mg/L gentamycin. Cultures were incubated in a 5% CO₂ chamber at 36°C subcultured semi-weekly.

Assay inoculum. *Leishmania* sp. and T₄ cells were diluted with fresh medium 24 h prior to use to ensure a log phase culture. The inoculum was standardized at the start of the assay with a spectrophotometer (Spectronic 21, Bausch & Lomb, Rochester, New York) in order to eliminate variations caused by different concentrations of cells growing at varying rates, and thus being inhibited differentially owing to cell concentration. Cell stock was centrifuged in a microcentrifuge at 200 - 400 g for 3 minutes and resuspended in fresh medium to give an initial cell concentration of approximately 5×10^5 /ml in the test wells.

Model for microwell plate assay procedure. Assays were performed in Corning sterile covered polystyrene 96-well round bottom tissue culture plates that were not tissue culture treated.

This is very important because cells will adhere to the surfaces of treated wells, and the absorbance readings will be inaccurate. All wells contained a uniform total volume for the assay.

Blank wells contained equal volumes of medium and sterile deionized double-distilled water. Control wells received medium, water, and inoculum, while test wells received the increasing amounts of test compound replacing water. Six replicates of each level of test compound were made. The standardized inoculum was stirred gently, under aseptic conditions, in a deep Petri dish, and suitable aliquots were pipetted into all but the blank plate wells. Absorbance readings were taken on a microplate spectrophotometer (Microplate Reader, Model MR 600, Dynatech Laboratories, Inc., Alexandria, Virginia) set in single wavelength mode with a suitable filter (490, 660 nm). The plate was shaken on a Vortex Genie-2 fitted with a 6-inch (15-cm) platform head containing a 96-well plate insert in order to ensure suspension of the cells just prior to reading the absorbance. Microwell plates containing leishmania were incubated in a 26°C incubator and read at 0, 24, 48, and 72 h. Microwell plates containing T₄ cells were incubated at 37°C with 5% CO₂ for the desired time. Toxicity studies were usually monitored at 0 and 72 h. Cellular toxicity was measured by determining the IC₅₀ (that concentration of an agent causing 50% inhibition compared with controls.)

To determine whether turbidity, observed photometrically in the microwells, would have a direct relationship to the cell concentration, we added several dilutions of cultures of Leishmania cells and human CEM T₄ cells to microwells. Absorbance was

measured with a microplate reader, and the well contents were counted on the Coulter counter, which had been calibrated against a hemocytometer for each cell line.

As a further check of the accuracy of this rapid method, we compared the IC_{50} of pentamidine, a known antileishmanial agent [2], by the microwell methods and the test tube method.

Test tube assay procedure. The assay procedure, a modification of the method of Kidder and Dewey [3], has been used for drug screening regularly in this laboratory. Scratch-free pyrex screw cap tubes (16 X 150 mm) were selected to match as closely as possible for use in the assay. The medium of Steiger and Black, supplemented with test compounds or water in a total volume of 5 ml, was used. The tubes (in triplicate) were incubated with loose caps in a slanted position (5°) in an incubator at $26^{\circ}C$ for 72 h. The tubes were vortexed before reading the absorbance at 660 nm, by use of a spectrophotometer equipped with a test tube chamber.

Cell counts using a Coulter counter. Aliquots from wells were counted at time 0 and 72 h with Model ZF Coulter counter (Coulter Electronics, Hialeah, Florida) with settings of $1/amp = 0.707$ and $1/aperture\ current = 2$ for the protozoan assays and 0.707, 16, respectively, for the T_4 lymphocyte assays.

Cell culture conditions for enzyme isolations. Promastigotes of Walter Reed strain 227 were used in these experiments. This strain has been previously identified as *Leishmania mexicana*

amazonensis (J. Decker-Jackson and P. Jackson, personal communication) and was obtained from the Leishmania Section of the Walter Reed Army Institute of Research. Promastigotes, were grown in brain heart infusion medium containing 37 g of brain heart infusion medium (Difco Laboratories, Detroit, Mich.) liter of water⁻¹, 10% heat inactivated serum, and 26 µg of hemin ml⁻¹. Cells were grown at 26°C in 2,000-ml wide Fernbach flasks containing 250 ml of brain heart infusion medium. Cells were harvested after 4 days during the exponential growth phase. The cell density was 4 X 10⁷ to 6 X 10⁷ cells ml⁻¹.

Protein assays. Protein concentrations were determined by either the dye-binding method (Bio-Rad laboratories, Richmond, Calif.) or a modified method. The modified method was performed in 96-well microplates by adding 80 µl of Bio-Rad dye and 20 µl of a column fraction. The plate was then read in a Dynatech 600 microplate reader at 575 nm.

Isolation and assay of S-Adenosylmethionine Synthetase. Using the method of Hoffman and Kunz (4), we optimized our enzyme assay for *L. mexicana* 227 promastigotes. Methionine adenosyltransferase activity was measured at 35°C in 100 µl of a standard assay mixture containing 150 mM KCl, 20 mM MgSO₄, 5 mM dithiothreitol, 50 mM Tris (pH 7.5), 5 mM ATP, and 10 µM L-[¹⁴C]methionine. The cationic [¹⁴C]adenosylmethionine formed was isolated by spotting 80-µl portions of reaction mixtures on 2.3-cm-diameter disks of Whatman P81 cellulose phosphate cation-exchange paper, removing unreacted methionine by washing in a beaker of

cold 0.1 M ammonium formate (pH 3.0), once with 95% ethanol, and once with ether. [^{14}C]-adenosylmethionine was quantified by liquid scintillation counting of dried disks under 5 ml of Fisher Scint Verse II.

SAM synthetase was isolated by suspending 8 g of pelleted *L. mexicana* 227 cells in buffer containing 50 mM Tris (pH 7.5), 10 mM MgCl_2 , 1 mM EDTA, and 1 mM dithiothreitol. The cells were sonicated three times for 15 s each time, and the cell suspension was centrifuged at 4°C for 90 minutes at 40,000 X g in an SW 55 Ti rotor. The cell extract (5.3 ml) was applied to a DEAE-cellulose column, and the above buffer was passed through the column until the A_{280} was less than 0.1. the enzyme was then eluted with a linear gradient of KCl (0 to 0.3M) in a volume of 80 ml.

**COMPOUND TESTED AGAINST
LEISHMANIA MEXICANA 227
(IC₅₀ uM)**

WR NUM	Name	Date	Mode of Action	Approved for Human Use	IC ₅₀ (uM)	IC ₅₀ (ug/ml)	Max. % Inhib.	Highest Conc. Tested(uM)	Comments
65105	WR 240811 AA				184.00				
65141	WR 263527 AA				185.00				
64811	WR 183751 AA						28.6	570	
64820	WR 184382 AA						13.7	500	
65080	WR 221858 AA						34.3	1000	
65150	WR 249888 AA						27.1	870	
65169	WR 249809 AA						28.5	670	
65178	WR 249841 AA						35.8	1000	
64831	WR 153335 AA						0	400	
64840	WR 171304 AA						0	400	
64859	WR 171333 AA						0	400	
64877	WR 182971 AA						0	400	
64886	WR 182968 AA						0	400	
64902	WR 183750 AA						0	1000	
64857	WR 217246 AA						0	500	
64975	WR 218555 AA						0	375	
64984	WR 218421 AA						0	375	
64993	WR 218418 AA						0	500	
65007	WR 218413 AA						0	500	
65025	WR 220048 AA						0	500	
65034	WR 220033 AA						0	500	
65114	WR 040320 AB						0	1000	
65123	WR 244633 AB						0	250	
65187	WR 248940 AA						0	1000	
64995	WR 183119 AA						0	1000	stimulation
64939	WR 184358 AA						0	800	stimulation
64946	WR 185204 AA						0	1000	stimulation
64966	WR 218368 AA						0	1000	stimulation
65016	WR 219884 AA						0	500	stimulation, precipitate noted in assay tubes
65043	WR 220001 AA						0	1000	stimulation
65052	WR 221235 AA						0	1000	stimulation
65070	WR 222058 AA						0	1000	stimulation
65098	WR 230639 AA						0	1000	stimulation, precipitate noted in assay tubes
65132	WR 249721 AA						0	500	stimulation
WR 2446							0	120	stimulation
	Azithromycin						25	1000	
	Azidothymidine						0	900	stimulation
	Dideoxycytidine						0	1000	

WR NUM	Name	Date	Mode of Action	Approved for Human Use	IC50 (uM)	IC50 (ug/ml)	Max. % Inhib.	Highest Conc. Tested(uM)	Comments
	Didoxynic acid						0	1000	
	Pentamidine isethionate				42.00		0	500	Sigma 1 - frozen sample, thawed
	Sulfamethoxazole				0.03				Sigma 2 - Freshly prepared
	Sinefungin, Sigma 1				0.24				
	Sinefungin, Sigma 2				0.21				
	Sinefungin, Walter Reed				0.24				
58705	Sinefungin, Calbiochem								
	Elephant garlic (protein extract)					12.5			
	Formycin B		RNA, protein synthesis	No			0	0.04	stimulation
	Cyclic Formycin A monophosphate		Unknown, Growth Inhibitor	No			0	0.06	stimulation
	Allopurinol riboside		RNA, protein synthesis	Now in trial			0	190	stimulation
	4-Aminopyrazole-pyrimidine		RNA, protein synthesis	No			0	76	stimulation
	N ⁶ -Methylaminopurine- β -ribofuranoside		Guanase, Adenine deaminase Nucleoside hydrolyase Transport purines	No					6.5uM Ki for Guanase
	β -Methylaminopurine- β -ribofuranoside		Transport of Nucleosides	No	250.00				
	Hypoxanthine- β -D-arabinofuranoside		Transport of Inosine	No	110.00				
	β -Methylpurine		Transport of Nucleosides	No	75.00				
	β -Methylxanthine-ribose		Transport of Adenosine	No	75.00				
	β -Mercaptopurine-ribose		Transport of Nucleosides	No	75.00				
	Adenosine, N ⁶ -cyclohexyl		Transport of Adenosine	No	75.00				
	β -Phenylthiophylline		Transport of Nucleosides	No	75.00				
	2-Mercaptopurimidine		Growth inhibition	No	230.00				
	5-Fluorouracil		Growth inhibition	Yes	300.00				
	4-Mercapto-2-pyrazolo [3,4-d] pyrimidine		Growth inhibition	No	750.00				
	Arachidonic Acid				350.00				
	Eicosapentaenoic Acid				860.00				
	Linoleic Acid				800.00				
02027	no name								insoluble, not tested
03006	WR 268613 AA								insoluble, not tested
02004	WR 268612 AA								insoluble, not tested
02031	WR 268603 AA								insoluble, not tested
02059	WR 268605 AA								insoluble, not tested
02066	WR 268607 AA								insoluble, not tested
02066	WR 268610 AA								insoluble, not tested
03045	WR 268614 AA								insoluble, not tested
03054	WR 268615 AA								insoluble, not tested
58588	WR 268317 AA				70.00				
21100	WR 243251 AC		1,2-Dimethyl-3-hydroxypyrid-4-one 7-Chloro-3-(2",4"-dichlorophenyl)-1-[[33'- (dimethylamino)propyl]imino]-1,2,3,4-tetrahydro- 9(10H)acridinone		178 (mM)				
29759	WR 250548 AB		(S)-7-Chloro-3-[2,4-dichlorophenyl]-1,2,3,4-tetrahydro-1-[[3-(dimethylamino)propyl]imino]- β -acridinol						insoluble, not tested
34170	WR 250547 AB		(R)-7-Chloro-3-[2,4-dichlorophenyl]-1,2,3,4-tetrahydro-1-[[3-(dimethylamino)propyl]imino]- β -acridinol				16	150	

IN	WR NUM	Name	Date	Mode of Action	Approved for Human Use	IC50 (uM)	IC50 (ug/ml)	Max. % Inhib.	Highest Conc. Tested(uM)	Comments
IL 56300	WR 162993 AB	1-(3,4-Dichlorophenyl)-3-(1-isopropyl-4,5-dioxo-2-imidazolidinylidene)-guanidine						8	202	
IM 02095	WR 268611 AA	no name								insoluble, not tested
IM 02097	WR 268602 AA	no name								insoluble, not tested
IM 02098	WR 268607 AA	no name								insoluble, not tested
IM 03063	WR 268616 AA	no name								insoluble, not tested
IM 03016	WR 257801 AB	no name								insoluble, not tested
IM 02666	WR 268601 AA	no name								to be tested
IM 02813	WR 268604 AA	no name								insoluble, not tested
M 02640	WR 268606 AA	no name								insoluble, not tested
M 02677	WR 268609 AA	no name								insoluble, not tested
M 08608								58.2	1000	test against higher concentration
K 73252	WR 238605 AC	6-[(4-Amino-1-methylbutylamino)-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline succinate 6-Methoxy-6-(6-deethylaminoheptylamino)lepidine, dihydrochloride								compound binds and PPT media components
K 01845	WR 008026 AF	6-[(4-Amino-1-methylbutylamino)-5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL-Tartrate				1 (mM)				
M 04186	WR 242511 AD					1.25 (mM)				
M 08175	WR 268607 AA	3-Deazasteromycin						22.3	1000	test against higher concentration
M 07616	WR 268670 AA	3-Deazasteromycin hydrochloride, hemihydrate						28.6	1000	test against higher concentration
B-1										tested against L. max. 222 resulting in an IC50 of 28 ug/ml
B-3										tested against L. max. 222 resulting in an IC50 of <<10
V-6a								32	50 ug/ml	
U-55								0	50 ug/ml	

COMPOUNDS TESTED AGAINST HUMAN CEM T. CELLS (IC₅₀ uM)

BN	WR_NUM	Name	IC50 (uM)	IC50 (ug/ml)	IC25 (uM)	Comments
		Sinefungin	11000	28.8		
		DFMO	10400	57.1		Eflornithine (DL-alpha-difluoromethylornithine)
		Sulfamethoxazole	3900	16.7		
	WR 2446	Naltrexone	2270	5.8		
		Flucytosine	1656	4.4		An Immune Modulator that stimulates CD4+ cells in vivo.
			> 1500	11.6		
	WR 183750		1020	2.2		
		TMP-SMX	52.6	0.18		Trimethoprim - Sulfamethoxale (Proloprim or Bactrim) in 1:19 ratio.
		Acyclovir	540	2.4		Zovirax
		Dapsone	> 500	2		
		Trimethoprim	420	1.4		
		AZT	220	0.8		Zidovudine
		Pentamidine	7	0.012		
		2'3'-Dideoxycytidine	6	0.028		
		Ketoconazole	2.3	0.004		
BL 59588			460			
BL 21100			92			
BL 34170			26			
BL 56390			96			
		Allopurinol Riboside	> 12300			
		Meglumine antimoniate (Glucantime)	> 12000			Meglumine antimoniate
		9-deazainosine	4000			
		Cyclic sinefungin	> 3000			
		Cordycepin	3000			
		SIBA	250			5-deoxy-5-(isobutylthio)-3-adenosine

BN	WR_NUM	Name	IC50 (uM)	IC50 (ug/ml)	IC25 (uM)	Comments
		Formycin B	13			
		SRIC				5'-o-sulfamoyl-1-B-D-ribofuranosyl triazole-3-carboxamide
		7-deazainosine	13			
		Formycin A	12			
		Allium sativus (Garlic)	< 8			
				11		11 ug protein/ml (0.001 of a clove/ml) This is made from a crude extract of raw garlic which is diluted in double-distilled water and sterile-filtered.
ZP 64831	WR 153335 AA		> 1000		390	
ZP 64840	WR 171304 AA		430		253	
ZP 64859	WR 171333 AA		> 1000		> 1000	
ZP 64877	WR 182971 AA		1004		325	
ZP 64886	WR 182968 AA		379		240	
ZP 64895	WR 183119 AA		> 1000		> 1000	
ZP 64902	WR 183750 AA		> 1000		317	
ZP 64911	WR 183751 AA		26		8	
ZP 64920	WR 184362 AA		927		259	
ZP 64939	WR 184358 AA		< 10		< 10	
ZP 64948	WR 185204 AA		> 1000		> 1000	
ZP 64957	WR 217246 AA		354		116	
ZP 64966	WR 218368 AA		218		81	
ZP 64975	WR 218555 AA		300		121	
ZP 64984	WR 218421 AA		927		510	
ZP 64993	WR 218418 AA		> 1000		> 1000	
ZP 65007	WR 218413 AA		> 1000		605	
ZP 65016	WR 219984 AA		422		10	
ZP 65025	WR 220048 AA		1000		44	
ZP 65034	WR 220033 AA		68		16	
ZP 65043	WR 220001 AA		388		10	
ZP 65052	WR 221235 AA		587		58	
ZP 65070	WR 222056 AA		> 1000		> 1000	
ZP 65089	WR 221656 AA		100		10	
ZP 65098	WR 230639 AA		> 500		50	
ZP 65105	WR 240811 AA		< 10		< 10	
ZP 65114	WR 040320 AB		> 1000		> 1000	
ZP 65123	WR 244633 AB		> 1000		410	


BN	WR_NUM	Name	IC50 (uM)	IC50 (ug/ml)	IC25 (uM)	Comments
ZP 65132	WR 249721 AA		95		28	
ZP 65141	WR 263527 AA		> 1000		> 1000	
ZP 65150	WR 249868 AA		851		373	
ZP 65169	WR 249909 AA		309		133	
ZP 65178	WR 249941 AA		546		218	
ZP 65187	WR 249940 AA		> 1000		529	
		7-Deazaaristomycin	19.6			
		Cyclic Formycin A	250			
		Oxyformycin B	2000			
		Sangivamycin	6.4			
		Spermidine	< 100			
HB-1						25% inhib. at 5 ug/ml
HB-3						21% inhib. at 5 ug/ml
PN-6a						22% inhib. at 5 ug/ml
DL-55						74% inhib. at 5 ug/ml

**The Toxicity of 34 Adenosine Analogs to Human CD4
T-Lymphocytes as measured in ug/ml.**

Compound:		ID50	ID25
ZP Number	WR Number	(ug/ml)	(ug/ml)
ZP 64939	WR 184358 AA	<4	<4
ZP 65105	WR 240811 AA	<4	<4
ZP 64911	WR 183751 AA	10	3
ZP 65034	WR 220033 AA	25	6
ZP 65089	WR 221656 AA	34	3
ZP 65132	WR 249721 AA	43	13
ZP 64966	WR 218368 AA	77	28
ZP 64975	WR 218555 AA	121	44
ZP 64886	WR 182968 AA	122	77
ZP 65043	WR 220001 AA	131	3
ZP 65169	WR 249909 AA	131	56
ZP 64840	WR 171304 AA	145	85
ZP 64957	WR 217246 AA	163	53
ZP 65016	WR 219984 AA	181	4
ZP 65052	WR 221235 AA	222	22
ZP 65178	WR 249941 AA	227	91
ZP 64831	WR 153335 AA	>214	83
ZP 65098	WR 230639 AA	336	17
ZP 64877	WR 182971 AA	347	112
ZP 64920	WR 184362 AA	352	98
ZP 65150	WR 249868 AA	353	155
ZP 65187	WR 249940 AA	358	189
ZP 65025	WR 220048 AA	371	16
ZP 65123	WR 244633 AB	388	159
ZP 65007	WR 218413 AA	>326	197
ZP 64902	WR 183750 AA	>470	149
ZP 64984	WR 218421 AA	510	143
ZP 64859	WR 171333 AA	>295	>295
ZP 64993	WR 218418 AA	>303	>303
ZP 64895	WR 183119 AA	>320	>320
ZP 64948	WR 185204 AA	>341	>341
ZP 65070	WR 222056 AA	>343	>343
ZP 65114	WR 040320 AB	>354	>354
ZP 65141	WR 263527 AA	>374	>374


						A Polymerase				B Polymerase			
							Active	Inactive Compounds Max. % Inhib. Highest Conc. Tested(um)		Active	Inactive Compounds Max. % Inhib. Highest Conc. Tested(um)		
Bottle No.	W/R No.	Name	Approved for Human Use				IC50	1000		IC50	1000		Comments
		COMDP						150			0		
		Arachidonic Acid					23-50*			40			*dependent on units of enzyme present
		Linoleic Acid					40			50			
		gamma-Linolenic Acid					40			40			
		Eicosapentaenoic Acid					140			207			
		Docosahexaenoic Acid					150			192			

COMPOUNDS TESTED AGAINST HUMAN CEM T4 CELLS (IC₅₀ uM)



Decreasing Effectiveness →


Very Effective Compounds for T4 Cells (IC50, μ M)



Very Effective Compounds for T4 Cells (IC50, uM)

Compound	IC50, uM
Ketoconazole	2.3
BJ 23346	5
BK 73252	5
BM 05816	5
2'3'-Dideoxycytidine	6
Sangivamycin	6.4
Pentamidine	7
Formycin A	8
WR 184358 AA	10
WR 240811 AA	10
7-deazainosine	12
Formycin B	13
SRTC	13
7-Deazaaristeomycin	19.6
BK 01845	25
BL 34170	26
WR 183751 AA	26
TMP-SMX	52.6
WR 220033 AA	68
BL 21100	92
WR 249721 AA	95
BL 56390	96
Spermidine	100
WR 221656 AA	100


Moderately Effective Compounds for T4 Cells (IC50, uM)



Moderately Effective Compounds for T4 Cells (IC50, uM)

Compound	IC50, uM
WR 218368 AA	218
AZT	220
Cyclic Formycin A	250
SIBA	250
WR 218555 AA	300
WR 249909 AA	309
WR 217246 AA	354
WR 182968 AA	379
WR 220001 AA	388
Trimethoprim	420
WR 219984 AA	422
WR 171304 AA	430
BL 59588	460
Dapsone	500
WR 230639 AA	500
Acyclovir	540
WR 249941 AA	546
WR 221235 AA	587
WR 249868 AA	851
WR 184362 AA	927
WR 218421 AA	927
WR 040320 AB	1000
WR 153335 AA	1000
WR 171333 AA	1000
WR 183119 AA	1000
WR 183750 AA	1000
WR 185204 AA	1000
WR 218413 AA	1000
WR 218418 AA	1000
WR 220048 AA	1000
WR 222056 AA	1000
WR 244633 AB	1000
WR 249940 AA	1000
WR 263527 AA	1000
WR 182971 AA	1004
WR 183750	1020


Least Effective Compounds for T4 Cells (IC50, μ M)




Least Effective Compounds for T4 Cells (IC50, uM)

Compound	IC50, uM
Flucytosine	1500
Naltrexone	1656
Oxyformycin B	2000
WR 2446	2270
Cordycepin	3000
Cyclic sinefungin	3000
Sulfamethoxazole	3900
9-deazainosine	4000
DFMO	10400
Sinefungin	11000
Meglumine antimoniate (Glucantime)	12000
Allopurinol Riboside	12300

Compounds for L. Mexicana (IC50, uM)




Very Effective Compounds for L. Mexicana (IC50, μ M)



Very Effective Compounds for L. Mexicana

Compound	IC50, uM
Sinefungin, Sigma 1	0.03
WR 254847 AB (Sinefungin, Walter Reed)	0.21
Sinefungin, Calbiochem	0.24
Sinefungin, Sigma 2	0.24
BM 05816	4.00
BJ 23346	5.00
BK 73252	5.00
BK 01845	12.00


Moderately Effective Compounds for L. Mexicana (IC50, μ M)



Moderately Effective Compounds for L. Mexicana

Compound	IC50, μ M
Pentamidine isethionate	42.00
WR 268317 AA	70.00
6-Mercaptopurine-riboside	75.00
6-Methlyoxypurine-riboside	75.00
6-Methlypurine	75.00
8-Phenyltheophylline	75.00
Adenosine, N ⁶ -cyclohexyl	75.00
Hypoxanthine-9-beta-D-arabinofuranoside	110.00
WR 263527 AA	165.00
WR 240811 AA	184.00
2-Mercaptopyrimidine	250.00
6-Methylaminopurine-9-ribofuranoside	250.00
5-Flouorouracil	300.00
Arachidonic Acid	350.00
Linoleic Acid	600.00
Eicoapentaenoic Acid	660.00
4-Mercapto-2-pyrazolo [3,4-d] pyrimidine	750.00


Least Effective Compounds for L. Mexicana (IC50, μ M)



Least Effective Compounds for L. Mexicana

Compound	IC50, uM
WR 006026 AF	1,000.00
WR 242511 AD	1,250.00
WR 243251 AC	178,000.00

Natural Compounds for L. Mexicana 222 (IC50, ug/ml)




Decreasing Effectiveness


Natural Compounds for L. Mexicana 222

Compound	IC50, ug/ml
HB-3	10.00
Elephant garlic (protein extract)	12.50
HB-1	25.00


**WRAIR Compound BJ 23346 Against
Leshmania mexicana DNA Polymerase A and
Chinese Hamster Ovary DNA Polymerase**




**WRAIR Compound BK 01845 Against
Leshmania mexicana DNA Polymerase A and
Chinese Hamster Ovary DNA Polymerase**




**WRAIR Compound BK 40735 Against
Leshmania mexicana DNA Polymerase A and
Chinese Hamster Ovary DNA Polymerase**



**WRAIR Compound BK 73252 Against
Leshmania mexicana DNA Polymerase A and
Chinese Hamster Ovary DNA Polymerase**



**WRAIR Compound BM 05816 Against
Leshmania mexicana DNA Polymerase A and
Chinese Hamster Ovary DNA Polymerase**



THE DNA POLYMERASES OF *LEISHMANIA MEXICANA*

SUMMARY

Two previously isolated DNA polymerases from the parasitic protozoan *Leishmania mexicana* were further characterized by exposure to inhibitors of mammalian DNA polymerases. DNA polymerase A, a high molecular weight enzyme, and DNA polymerase B, a b-like DNA polymerase were compared to each other and to their mammalian counterparts regarding pH optimum, utilization of templates, and response to various inhibitors and ionic strengths. The results suggest the DNA polymerases from *L. mexicana* differ from the host enzymes and may offer a target for chemotherapeutic intervention.

INTRODUCTION

Five classes of DNA polymerase (a, b, c, d and e) have been isolated from higher eukaryotic cells (5-9) and a, b and c-like polymerases from parasitic protozoa (1-18). DNA polymerases a, d and e are nuclear enzymes associated with chromosomal replication; b is a low molecular weight nuclear enzyme involved in DNA repair (2,15,16), and c which has been isolated from mitochondria is believed to be responsible for mitochondrial DNA replication (6,9,21).

We have been studying DNA replication in the kinetoplast parasite *Leishmania mexicana* and have begun studies to characterize the major polymerase activities in these parasites for the purpose of comparing

them to host polymerases, particularly a and b. Although North and Wyler reported studies of *in vivo* DNA replication of *Leishmania* parasites (22), this laboratory is the first to report the isolation and characterization of the leishmanial DNA polymerases *in vitro* (10-12). Others have described purification of a-like, b-like (13) and c-like polymerases (18) from the parasitic protozoans *Crithidia fasciculata* and an a-like polymerase from *Trypanosoma brucei* (14) and *Trypanosoma cruzi* (15).

The purpose of this study is to compare the major DNA polymerase activities (A and B) isolated from *Leishmania mexicana* to a and b polymerases isolated from other sources.

MATERIALS AND METHODS

Test organism

Leishmania mexicana amazonensis (Walter Reed strain 227) obtained from the *Leishmania* section of the Walter Reed Army Institute of Research were grown in brain heart infusion media as previously described (10).

Preparation of Compounds

Aphidicolin (Sigma Chemical Co., St. Louis, MO) was prepared in dimethylsulfoxide (DMSO) as a 5 mM stock and diluted with water so that the final concentration of DMSO in the assay was no more than 0.16% (v/v). Suramin, purchased from Miles Pharmaceuticals (West Haven, CT), was made into a 70 mM stock solution in 10 mM Tris pH 7.5. Further dilutions were made with the same buffer. Butylphenyl dGTP (BuPdGTP), carbonyldiphosphonate (COMDP) and the phosphonoacetic acid derivatives

BrPAA, ClPAA, FPAA, and F₂PAA were generous gifts from Dr. G. Wright, University of Massachusetts Medical Center (Worcester, MA), and were prepared in aqueous solution at the appropriate concentrations. All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).

Isolation of DNA polymerases

DNA polymerase A, a high molecular weight DNA polymerase sensitive to N-ethylmaleimide (NEM) was isolated from *L. mexicana* promastigotes as described (11). A low molecular weight DNA polymerase classified as a b-like enzyme was isolated from promastigotes as described (12). This enzyme will be referred to as DNA polymerase B, to distinguish it from mammalian enzymes and to follow the designation used by Holmes et al. (13) for the *Crithidia fasciculata* DNA polymerases.

Drug assays

The inhibitory properties of several compounds were determined by pre-incubating the enzyme and drug in the assay mix. In order to characterize the enzymes, selective inhibitors of mammalian DNA polymerases were tested against both enzymes. DNA polymerase A was assayed at 35°C as described (11). DNA polymerase B activity was measured at 35°C as previously described (12).

. RESULTS AND DISCUSSION

Isolation of DNA polymerases

Two types of DNA polymerase activity were separated using affinity chromatography with denatured DNA cellulose. The two enzyme activities were designated as DNA polymerase A (11) and a b-like DNA polymerase (12).

according to their molecular weight, pH optimum and response to *N*-ethylmaleimide.

The B enzyme (pol B) was less stable than the DNA polymerase A (pol A) at all stages of the purification. The use of a mixture of protease inhibitors as well as glycerol during the isolation procedures was essential for stability of the DNA polymerases. In addition, the use of a freshly prepared assay mix was critical in obtaining pol B enzyme activity. Difficulty in detecting a low molecular weight DNA polymerase in parasitic protozoans has resulted in conflicting reports from some groups regarding the presence of a low molecular weight DNA polymerase in *Trypanosoma brucei* (9 14). In addition, studies on *T. cruzi* detected only one DNA polymerase of high MW and no b-like enzymes (15).

Proper characterization of the DNA polymerases from *L. mexicana* is essential in order to compare them with the host enzymes, a first step in a strategy to develop chemotherapeutic agents. To date, all enzymes isolated from parasitic protozoans have been found to share some, but not all, of the characteristics of the mammalian enzymes (9 11-18).

Characterization Studies

Pol A was slightly stimulated by NaCl or KCl at concentrations of less than 15 mM, but rapidly inactivated by higher concentrations of salt (11). DNA polymerase B was slightly stimulated by 5 mM KCl only, but was more resistant to inactivation by higher concentrations of NaCl or KCl, with 35% of the activity remaining in the presence of 200 mM NaCl and 43% of the activity remaining in the presence of 200 mM KCl (12) Mammalian DNA polymerase α is inhibited by high (≥ 100 mM)

concentrations of salt, whereas DNA polymerases b and d are stimulated by such concentrations (6).

The optimum pH of the pol A enzyme is mildly acidic to neutral at 6.7, whereas the optimum pH of the pol B enzyme is basic, at 9.0. Table 1 shows a comparison of the activity of the enzymes with several template-primers. The pol A had a template preference for activated DNA and used poly(dA)·oligo(dT)₁₂₋₁₈ equally as well, with only 60% of the activity when poly(dC)·oligo(dT)₁₂₋₁₈ was the template (11). Pol B showed a six-fold preference for poly(dC)·oligo(dT)₁₂₋₁₈ as the template over activated DNA (8). The preferred template for DNA polymerases a and b is activated DNA, whereas the mitochondrial DNA polymerase is more active with poly(rA)·Oligo(dT). A notable point is the inability of pol B to utilize Mn⁺² as the divalent cation activator. In contrast, mammalian DNA polymerase b is capable of using both Mn⁺² and Mg⁺² (6).

Inhibitor Studies

Exposure of the enzymes to specific DNA polymerase inhibitors showed the *L. mexicana* enzymes to be different from one another and from mammalian enzymes in their sensitivity to various compounds (Table 2). Both enzymes were resistant to aphidicolin, a mammalian DNA polymerases a, d and e inhibitor. The response of these enzymes to the mammalian DNA polymerase a inhibitor BuPdGTP was interesting. In the presence of 100 μ M dGTP, Pol B was twenty fold more sensitive to this compound than Pol A with a concentration that inhibits activity by 50% (IC₅₀) of 5.4 μ M, whereas the Pol A was inhibited with an IC₅₀ of 100 μ M. Phosphonoacetic acid (PAA) was a weak inhibitor of the Pol A with only 35% inhibition at 2 mM. Pol B was resistant to PAA at concentrations of up to 2 mM. Mammalian b polymerase has been found to be resistant to

inhibition by this compound (6). Several PAA analogues (25) were tested against the *L. mexicana* DNA polymerases (Table 2). Pol B was completely resistant to inhibition by the fluoro, bromo, chloro, and difluoro analogues of PAA (FPAA, BrPAA, ClPAA, F₂PAA; respectively). Pol A was resistant to BrPAA, ClPAA, and F₂PAA. FPAA, a monohalogenated derivative of PAA, inhibited pol A with an IC₅₀ of 130 μ M, resulting in over a ten fold increase in inhibition compared to PAA. FPAA also exhibited potent inhibition of the calf thymus DNA polymerases α and δ [Table 2; (25)]. COMDP, a specific inhibitor of mammalian DNA polymerase δ (19, 26) and Dr. G. Wright, personal communication), was inhibitory to both enzymes from *L. mexicana*. The Pol A enzyme was more sensitive to COMDP than the pol B with IC₅₀'s of 150 and 200 μ M, respectively (Table 2).

The response of these *L. mexicana* enzymes to non-specific inhibitors showed the unique properties of each enzyme (Table 2). Hemin, a critical nutritional component of the leishmanial growth media (10) was found to inhibit both enzymes, inhibiting pol B with an IC₅₀ of 60 μ M versus an IC₅₀ of 90 μ M for the pol A. Hemin inhibits DNA synthesis reversibly by binding DNA polymerase and causing it to dissociate from the template (27). Suramin, a drug used in the treatment of trypanosomiasis that has also been found to be a strong competitive inhibitor of the reverse transcriptase of a number of animal retroviruses (28), was found to be a potent inhibitor of the *L. mexicana* DNA polymerases. Suramin gave an IC₅₀ of 8 μ M, for pol A and 3 μ M, for pol B (Table 2).

Our characterization studies have shown the *L. mexicana* pol A and pol B to differ from each other in molecular weight, pH optimum,

template specificity, and response to salt and inhibitors. In addition, our studies have shown that pol A and pol B share similar properties such as pH optimum, molecular weight, and sensitivity to specific inhibitors such as NEM with their mammalian counterparts. The assignment of pol A to a specific class among the eukaryotic DNA polymerases is made difficult by its utilization of template (Table 1) and by the particular response of this enzyme to inhibitors (Table 2). Although this high molecular weight enzyme shows a-like properties such as inhibition by NEM and salt, insensitivity to ddTTP, and preference for Mg^{+2} and activated DNA, it also displays characteristics that do not fit the a type. Pol A also shows characteristics of the d type, such as resistance to aphidicolin and utilization (although at low levels, Table 1) of ribonucleotide template when Mn^{+2} is the divalent cation. On the other hand, the low sensitivity to BuPdGTP and the somewhat high sensitivity to COMDP point toward characteristics of the DNA polymerases d and e (24).

Pol B can be more easily classified as a b-like enzyme based on its low molecular weight, resistance to NEM, and sensitivity to ddTTP. However, Pol B failed to crossreact with an anti-recombinant mouse DNA polymerase b antiserum using enzyme neutralization studies (12). Using enzyme neutralization studies, as well as immunodiffusion and immunoelectrophoresis, Chang and Bollum showed that *T. brucei* DNA polymerase b did not crossreact with an antiserum against calf thymus DNA polymerase b (29).

Observations of differences with the mammalian polymerase have been made on the enzymes of other protozoans (11-18 24,29) suggesting that DNA replication in higher eukaryotes and protozoans may differ.

Such differences are being characterized in this laboratory in the search for potential anti-parasitic agents.

Table 1.

Template specificity of the *L. mexicana* DNA polymerases A and B.

Concentrations of divalent cations were 8 mM MgCl₂ or 0.5 mM MgCl₂.

Adapted from Nolan et al (7) and Nolan and Rivera (8).

TEMPLATE-PRIMER	Labelled Nucleotide	Divalent Cation	% of Activity Relative to activated DNA with [methyl- ³ H]dTTP	
			DNA pol A	DNA pol B
Activated DNA	dTTP	Mg ⁺²	100	100
	dTTP	Mn ⁺²	18	0
poly(rA) · oligo(dT) ₁₀	dTTP	Mg ⁺²	3	0.9
	dTTP	Mn ⁺²	31	0.9
poly(dA) · oligo(dT) ₁₂₋₁₈	dTTP	Mg ⁺²	99.2	149
	dTTP	Mn ⁺²	27.5	0
Activated DNA	dGTP	Mg ⁺²	1.76	17
	dGTP	Mn ⁺²	0.4	0
poly(rC) · oligo(dG) ₁₀	dGTP	Mg ⁺²	0	2
	dGTP	Mn ⁺²	1.3	0
poly(dC) · oligo(dG) ₁₂₋₁₈	dGTP	Mg ⁺²	57.8	650
	dGTP	Mn ⁺²	5.4	0.9

Table 2.

IC₅₀ values of several DNA polymerase inhibitors on the *L. mexicana* Pol A and pol B (7,8). The IC₅₀ values for the mammalian DNA polymerases indicate representative data obtained from published values in the literature (2,19,21,22,25). Enzymes found to be resistant to inhibition were marked as R.

Inhibitor	DNA polymerase						
	Mammalian					<i>L. mexicana</i>	
	a	b	c (1M)	d	e	A	B (1M)
AraCTP	^a	^a	-	-	-	R	>500 1M
Aphidicolin	2	R	R	2	15	R	R
NEM	<100	>10 mM	<100	<1000	-	<1000	R
BuPdGTP	.3	^b	>100	>10	>10	100	5.4
ddTTP	R	2	.05	R	-	R	7.5
PAA	71-710 ^c	R	71-710 ^c	-	-	1500	R
FPAA	20	-	-	2	-	130	R
BrPAA	160	-	-	20	-	R	R
ClPAA	120	-	-	70	-	R	R
F ₂ PAA	300 ^d	-	-	200 ^d	-	R	R
COMDP	300	-	-	40	200 ^e	150	200
Suramin	-	-	-	-	-	8	3
Hemin	-	-	-	-	-	90	60

^aIt has been reported that as a rule, mammalian polymerase b is less sensitive than polymerase a with K_i values ranging from 2 - 4 1M for polymerase a versus 13 - 32 1M for polymerase b (2). ^bTo our knowledge there is no published data on the inhibition of polymerase b by BuPdGTP. However, it has been reported that polymerase b is weakly inhibited by BuPdGTP (24). ^cConcentration range at which DNA polymerases a and c are reportedly inhibited by PAA (2). ^dValues obtained using poly(dA)·oligo(dT)₁₂₋₁₈ as the template (21). ^eThe same study reported 93% inhibition of DNA polymerase d from Hela cells by 15 1M COMDP using poly(dA)·oligo(dT) (22).

REFERENCES

1. Steiger, R.F., Black, C.D.V. (1980) *Acta Tropica* 37:195-199
2. Jiminez Gde, Ercoli N. (1965) *Exp. Parasitol* 17:302-308
3. Kidder, G.W., Dewey VC (1948) *Proc. Natl. Acad Sci USA* 34:81-88
4. Hoffman, J.L. and Kunz, G.L. (1977) *Biochem. Biophys. Res. Commun.* 77:1231-1236
5. Scovassi, A.I., Plevani, P., and Bertazzoni, U. (1980) *Trends Biochem. Sci* 5, 335-337.
6. Fry, M., and Loeb, L.A. (1985) *Animal Cell DNA Polymerases*, CRC Press, Inc., Boca Raton, FL.
7. Loeb, L.A. (1974) in *The Enzymes* (Boyer, P.D. ed) pp. 174-209, Academic Press, New York.
8. Wang, T.S.F. (1991) *Annu. Rev. Biochem.* 60, 513-552.
9. Chang, L.M.S., Cheriatundam, E., Mahoney, E.M. and Cerami, A. (1980) *Science* 208, 510-511.
10. Nolan, L.L. (1987). *Antimicrob. Agents Chemoter.* 31,1542-1548.
11. Nolan, L.L., Rivera, J.H. and Khan, N.N. (1992) *Biochim. Biophys. Acta.* In Press
12. Nolan, L.L. and Rivera, J.H. (1991) *Biochem. Int.* 25, 499-508.
13. Holmes, A.W., Cheriatundam, E., Kalinski, A. and Chang, L.M.S. (1984) *Molec. Biochem. Parasitol.* 10, 195-205
14. Dube, D.K., Williams, G.S. and Williams, S.C. (1979) *Biochim. Biophys. Acta* 561, 10-16.
15. Solari, A., Tharaun, D., Repetto, Y., Aldunate, J., Morello, A., and Litvak, S. (1983) *Biochem. Int.* 7, 147-157.

16. Abu-Elheiga, L., Spira, D.T. and Bachrach, U. (1990) Exp. Parasitol 71, 21-26.
17. Bzik, D.J. and Fox, B.A. (1991) Mol. Biochem. Parasitol. 49, 289-296.
18. Torri, A.F. and Englund, P.T. (1992) J. Biol. Chem. 267, 4786-4792.
19. Matsukage, A., Nishikawa, K., Ooi, T., Seto, Y., and Yamaguchi, M. (1987) J. Biol. Chem. 262, 8960-8962.
20. Wilson, S., Abbotts, J., and Widen, S. (1988) Biochim. Biophys. Acta 949, 149-157.
21. Burgers, P.M., Bambara, R.A., Campebell, J.L. Chang, L.M.S., Downey, K.M., Hubscher, U., Lee, M.Y., Linn, S.M., So, A.G., and Sparadi, S. (1990) Eur. J. Biochem. 191, 617-618.
22. North, T.W. and Wyler, D. (1987) Mol. and Biochem. Parasitol. 22, 215-221.
23. Bambara, R.A. and Jessee, C.B. (1991) Biochim. Biophys. Acta. 1088, 11-24.
24. DeVries, E., Stam, J.G., Franssen, F.F.J., Van der Vliet, P.C., Overdulve, J.P. (1991) Molec. Biochem. Parasitol. 45, 223-232.
25. Talanian, R.V., Brown, N.C., McKenna, C.E., Ye, T-G., Levy, J.N., Wright, G.E. (1989) Biochemistry 28, 8270-8274.
26. Syvaioja, J., Suomensaaari, S., Nishida, C., Goldsmith, J.S., Chui, G.S.J., Jain, S., Linn, S. (1990) Proc. Natl. Acad. Sci. USA 87, 6664-6668.
27. Byrnes, J.J., Downey, K.M., Esserman, L., So, A.G. (1975) Biochemistry 14, 796-799.
28. De Clerq, E. (1988). Adv. Drug Res. 17, 1-59.

29. Chang, L.M.S., Bollum, F.J. (1981) J. Biol. Chem. 256, 494-498.
30. Burgers, P.M.J. (1989). Prog. Nucl. Acid. Res. Mol. Biol. 37, 235-280.

DISTRIBUTION LIST

12 copies	Director Walter Reed Army Institute of Research Walter Reed Army Medical Center ATTN: SGRD-UWZ-C Washington, DC 20307-5100
1 copy	Commander US Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick, Frederick, Maryland 21701-5012
12 copies	Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, Virginia 22304-6145
1 copy	Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
1 copy	Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100